257 related articles for article (PubMed ID: 32505609)
1. Low-Dose-Rate Brachytherapy Combined With Ultrahypofractionated Radiation Therapy for Clinically Localized, Intermediate-Risk Prostate Cancer: Results From a Prospective Trial.
Kollmeier MA; McBride S; Varghese M; Debonis D; Zhang Z; Cohen G; Damato AL; Mychalczak B; Gewanter R; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):905-913. PubMed ID: 32505609
[TBL] [Abstract][Full Text] [Related]
2. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
3. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
5. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
8. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
10. Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy.
Gómez-Iturriaga Piña A; Crook J; Borg J; Ma C
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):422-7. PubMed ID: 20832665
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer.
Kollmeier MA; Pei X; Algur E; Yamada Y; Cox BW; Cohen GN; Zaider M; Zelefsky MJ
Brachytherapy; 2012; 11(4):271-6. PubMed ID: 22192495
[TBL] [Abstract][Full Text] [Related]
12. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
13. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
[TBL] [Abstract][Full Text] [Related]
14. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.
Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M
Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713
[TBL] [Abstract][Full Text] [Related]
15. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer.
Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer.
Potters L; Rana Z; Lee L; Cox BW
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):334-342. PubMed ID: 30721721
[TBL] [Abstract][Full Text] [Related]
17. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
[TBL] [Abstract][Full Text] [Related]
18. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
Lee HK; Adams MT; Motta J
Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
[TBL] [Abstract][Full Text] [Related]
19. Urinary symptom flare following I-125 prostate brachytherapy.
Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
[TBL] [Abstract][Full Text] [Related]
20. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up.
Keyes M; Miller S; Moravan V; Pickles T; Liu M; Spadinger I; Lapointe V; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):649-55. PubMed ID: 19211199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
